Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cholinergic Degeneration in Cognitive Fluctuations in Lewy Body Dementia
NCT07284290Phase 4Recruiting
- Sponsor
- Virginia Commonwealth University
- Start
- Dec 2025
- Primary completion
- Nov 2029
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 4 trial of galantamine in Lewy body dementia (LBD), Parkinson's disease dementia (PDD), sponsored by Virginia Commonwealth University. Started Dec 2025; status: recruiting.
02
Drugs
galantamine
03
Conditions
Lewy body dementia (LBD)Parkinson's disease dementia (PDD)
Beyond the preview
Go deeper on NCT07284290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07284290.